These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18846268)

  • 1. Oritavancin for skin infections.
    Anderson DL
    Drugs Today (Barc); 2008 Aug; 44(8):563-75. PubMed ID: 18846268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oritavancin: an investigational lipoglycopeptide antibiotic.
    Karaoui LR; El-Lababidi R; Chahine EB
    Am J Health Syst Pharm; 2013 Jan; 70(1):23-33. PubMed ID: 23261897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
    Crandon J; Nicolau DP
    Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oritavancin: a long-acting antibacterial lipoglycopeptide.
    Kaasch AJ; Seifert H
    Future Microbiol; 2016 Jul; 11():843-55. PubMed ID: 27161039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oritavancin: A Long-Half-Life Lipoglycopeptide.
    Saravolatz LD; Stein GE
    Clin Infect Dis; 2015 Aug; 61(4):627-32. PubMed ID: 25900171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains.
    Bouza E; Burillo A
    Int J Antimicrob Agents; 2010 Nov; 36(5):401-7. PubMed ID: 20729040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.
    Dunbar LM; Milata J; McClure T; Wasilewski MM;
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3476-84. PubMed ID: 21537018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.
    Poulakou G; Giamarellou H
    Expert Opin Investig Drugs; 2008 Feb; 17(2):225-43. PubMed ID: 18230056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oritavancin: A Novel Lipoglycopeptide.
    Mattox J; Belliveau P; Durand C
    Consult Pharm; 2016 Feb; 31(2):86-95. PubMed ID: 26842686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
    Roberts KD; Sulaiman RM; Rybak MJ
    Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
    Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
    Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
    Wu G; Truong J; Lee S; Elnadoury O; Kuan W; Abraham T; Wu A; Liu M
    Expert Rev Anti Infect Ther; 2015 Apr; 13(4):409-16. PubMed ID: 25661747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults.
    Chang MH; Kish TD; Fung HB
    Clin Ther; 2010 Dec; 32(13):2160-85. PubMed ID: 21316534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia.
    Rubino CM; Van Wart SA; Bhavnani SM; Ambrose PG; McCollam JS; Forrest A
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4422-8. PubMed ID: 19635952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose oritavancin in the treatment of acute bacterial skin infections.
    Corey GR; Kabler H; Mehra P; Gupta S; Overcash JS; Porwal A; Giordano P; Lucasti C; Perez A; Good S; Jiang H; Moeck G; O'Riordan W;
    N Engl J Med; 2014 Jun; 370(23):2180-90. PubMed ID: 24897083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy.
    Van Bambeke F
    Curr Opin Investig Drugs; 2006 Aug; 7(8):740-9. PubMed ID: 16955686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin.
    Delaportas DJ; Estrada SJ; Darmelio M
    Pharmacotherapy; 2017 Aug; 37(8):e90-e92. PubMed ID: 28543367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.